ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe

Core Viewpoint - AngioDynamics, Inc. has launched the RECOVER-AV clinical trial to evaluate the AlphaVac Multipurpose Mechanical Aspiration F1885 System for treating acute intermediate-risk pulmonary embolism (PE), aiming to support its adoption in the European market where PE prevalence is significantly higher than in the U.S. [1][3] Group 1: Clinical Trial Details - The RECOVER-AV trial is a prospective, multinational, single-arm study enrolling patients across 20 European hospital sites, following the successful APEX-AV trial in the U.S. [1][3] - The trial will monitor patients for 12 months, assessing functional outcomes at 30 days, six months, and 12 months post-procedure, with a focus on reducing the right ventricular/left ventricular ratio and minimizing major adverse events [3][4]. - The AlphaVac F1885 System has received CE Mark approval, indicating its potential to enhance PE treatment options in a high-need market [3][4]. Group 2: Market Context and Growth Prospects - The pulmonary embolism market was valued at $1.8 billion in 2023 and is projected to grow to $3.3 billion by 2034, with a compound annual growth rate (CAGR) of 5.5% [5]. - Growth in PE diagnosis is driven by advancements in imaging technologies, particularly Computed Tomography Pulmonary Angiography and Magnetic Resonance Angiography, which are improving detection rates and treatment options [5]. Group 3: Company Performance and Stock Trends - Following the announcement of the RECOVER-AV trial, AngioDynamics' shares fell by 2.1% to close at $7.54, reflecting market reactions to the news [2]. - Year-to-date, AngioDynamics' shares have decreased by 3.8%, contrasting with the industry's growth of 9.7% and the S&P 500's increase of 19.6% [7]. - AngioDynamics has consistently surpassed earnings estimates in the past four quarters, achieving an average surprise of 28.61% [9].